Aktienanalyse zu BioStem Technologies, Inc. (BSEM)BSEMBioStem Technologies, Inc.

BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines. It operates in the Healthcare sector.

BSEM is not a good buy right now due to its low current price of $1.12, a very low RSI of 28.465 indicating oversold conditions, and a staggering 75.59% decline over the past year. The company has also reported negative net income for the last two quarters, with losses of -$8,819,705 in Q1 2026 and -$8,971,360 in Q2 2026, which raises concerns about its financial health.